Sanofi A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi (SNY) and Johnson & Johnson’s (

Johnson & Johnson On December 9, 2024, Johnson & Johnson (JNJ) announced new results from the Phase 3 CARTITUDE-4 study demonstrating that a single infusion of CARVYKTI®  has significantly increased minimal residual disease (MRD) negativity rates in patients with relapsed or refractory multiple myeloma (RRMM) patients who were lenalidomide-refractory and had received one to three prior lines . . . This content is for paid subscribers. …

Johnson & Johnson New TECNIS Odyssey On September 30, 2024, Johnson & Johnson (JNJ) announced expanding the roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC - IOL), TECNIS Odyssey, in the U.S. TECNIS Odyssey IOL is built on the TECNIS platform, providing two . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Johnson & Johnson FDA Approval Yesterday, September 11, 2024,  Johnson & Johnson (JNJ) announced that the FDA has approved TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC) - a chronic disease of the large intestine in which the lining of the colon becomes inflamed.  About Ulcerative Colitis Ulcerative colitis is a form of inflammatory bowel . . . This …

Johnson & Johnson in the NEWS Today, Apr. 5, 2024 - Johnson & Johnson (JNJ) and Shockwave Medical (

Johnson & Johnson’s Janssen Pharmaceutical AKEEGA Johnson & Johnson (JNJ) owned Janssen Pharmaceutical announced that the U.S. FDA has approved AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), which no longer responds to androgen deprivation therapy and has spread to other …

The Stock Market Continues to Plummet Indeed, the Stock Market continues to decline, losing investors' profits.   Each time the Market plummets it takes with it promising firms' stocks but when the biotech stocks plummet new reasons are always claimed for the decline. Today's claimed reason for the deep losses is the tension between Russia and Ukraine, which, as it happens, is not the only …

Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio stocks’ targets for the year failed to materialize; nobody not even the authorities were capable of predicting the pandemic, which continues to plague the world. As 2021 approached, we were unable to the End of the Year issue on time as we lacked the information required for the fair …

Johnson & Johnson Receives an EUA from the U.S. FDA We appreciate the U.S. Food and Drug Administration's emergency use authorization (EUA) for the third vaccine for the prevention of SARS-CoV-2 (the virus that causes COVID-19). Three vaccines are definitely better than two and now, the third vaccine, which belongs to Johnson & Johnson (

Johnson & Johnson COVID-19 Vaccine According to a new analysis posted online by the FDA, the Johnson & Johnson (JNJ) vaccine is providing strong protection against severe disease and death related to COVID-19 infection. The vaccine may reduce the spread of the virus from vaccinated people. The vaccine is said to have a 72% efficacy rate in the U.S. and 64% in South Africa. The …

Johnson & Johnson ENSEMBLE Trial for Its COVID-19 Vaccine Candidate Johnson & Johnson (JNJ) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial, ENSEMBLE, for its COVID-19 vaccine candidate, JNJ-78436735. The initiation of the ENSEMBLE trial follows positive interim results from Phase 1 . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Halozyme and PTC Therapeutics: Near-Term Game-Changing PDUFAS Some of the Prohost Portfolio selected companies are having near term PDUFAS which we believe will have a positive outcome. Indeed the FDA approvals are expected to tremendously boost these firms' values. Today we present two selected Biotech firms from the Prohost Portfolio.   Halozyme Halozyme (HALO) has two upcoming important

Presenting Fate Therapeutics Today we are presenting Fate Therapeutics (FATE); a clinical-stage company developing programmed cellular immunotherapies for cancer and immune disorders. Our enthusiasm for this firm is due to its announcement that it signed a global collaboration agreement with the Johnson & Johnson (

The Week in Review #49 The Stars from the Weeks Preceding the Novel Coronavirus Outbreak  Forty Seven Forty Seven (FTSV) was added to the

Gilead Stock Is UP Gilead Sciences' (GILD) provided its antiviral experimental drug remdesivir to physicians for a small number of patients infected with the 2019 novel coronavirus (2019-nCoV) as a possible emergency savior . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation by Bayer demonstrated improvement in the treatment of non-metastatic castration-resistant prostate cancer. Separate presentations by Bristol-Myers and Janssen also demonstrated improvement in metastatic castration-resistant prostate cancer. Non-Metastatic Castration Resistant Prostate Cancer Bayer Results from pivotal Phase 3 ARAMIS trial with Bayer’s (BAYRY) and Orion Corporation’s jointly-developed product darolutamide plus …